Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions
Cet article passe en revue les avancées récentes concernant le traitement des cancers métastatiques de la prostate et les biomarqueurs permettant d'effectuer un choix thérapeutique ou d'évaluer les anticancéreux en cours de développement
Purpose of review : Summarizes recent advances in the treatment of metastatic castration-sensitive and castration-resistant prostate cancer.
Recent findings : New randomized data suggest a survival advantage to early abiraterone in castration-sensitive metastatic prostate cancer. Prospective and retrospective studies are examining sequencing of existing cytotoxic and androgen-receptor-targeted therapies in both castration-sensitive and castration-resistant disease. Genomic analysis of both circulating tumor cells and circulating tumor nucleic acids is being examined as a potential method for selecting existing therapies and identifying novel therapeutic targets. Finally, immunotherapy combinations are being evaluated in the setting of advanced prostate cancer.
Summary : In this review, we hope to summarize the recent data supporting the use of early abiraterone in castration-sensitive metastatic prostate cancer and discuss how this data might be incorporated with previous trials showing a survival advantage to early docetaxel. We present recent series examining sequencing of approved therapies as well as trials evaluating novel biomarkers and genomic analyses designed to help choose from among approved therapies or evaluate drugs in development. Lastly, we review ongoing trials examining novel immunotherapy combinations in advanced prostate cancer.
Current Opinion in Oncology , résumé, 2017